JP2012510461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012510461A5 JP2012510461A5 JP2011538092A JP2011538092A JP2012510461A5 JP 2012510461 A5 JP2012510461 A5 JP 2012510461A5 JP 2011538092 A JP2011538092 A JP 2011538092A JP 2011538092 A JP2011538092 A JP 2011538092A JP 2012510461 A5 JP2012510461 A5 JP 2012510461A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 1
- 229960001924 melphalan Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08291116.5 | 2008-11-28 | ||
| EP08291116A EP2191840A1 (en) | 2008-11-28 | 2008-11-28 | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| PCT/IB2009/055389 WO2010061357A1 (en) | 2008-11-28 | 2009-11-27 | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107404A Division JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012510461A JP2012510461A (ja) | 2012-05-10 |
| JP2012510461A5 true JP2012510461A5 (OSRAM) | 2012-11-22 |
Family
ID=40578382
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011538092A Withdrawn JP2012510461A (ja) | 2008-11-28 | 2009-11-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2015107404A Active JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2017037860A Pending JP2017141233A (ja) | 2008-11-28 | 2017-03-01 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015107404A Active JP6148696B2 (ja) | 2008-11-28 | 2015-05-27 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
| JP2017037860A Pending JP2017141233A (ja) | 2008-11-28 | 2017-03-01 | Ｃｄ３８を特異的に認識する抗体およびメルファランを含有する抗腫瘍性組合せ剤 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9259406B2 (OSRAM) |
| EP (2) | EP2191840A1 (OSRAM) |
| JP (3) | JP2012510461A (OSRAM) |
| KR (1) | KR101733252B1 (OSRAM) |
| CN (1) | CN102264385B (OSRAM) |
| AR (1) | AR074219A1 (OSRAM) |
| AU (1) | AU2009321249B2 (OSRAM) |
| BR (1) | BRPI0921864B1 (OSRAM) |
| CA (1) | CA2744990C (OSRAM) |
| CL (1) | CL2011001254A1 (OSRAM) |
| CO (1) | CO6440557A2 (OSRAM) |
| CR (1) | CR20110280A (OSRAM) |
| EA (1) | EA026867B1 (OSRAM) |
| EC (1) | ECSP11011062A (OSRAM) |
| HN (1) | HN2011001417A (OSRAM) |
| IL (1) | IL213116B (OSRAM) |
| MA (1) | MA32896B1 (OSRAM) |
| ME (1) | ME01136B (OSRAM) |
| MX (1) | MX342625B (OSRAM) |
| MY (1) | MY164577A (OSRAM) |
| NI (1) | NI201100105A (OSRAM) |
| NZ (1) | NZ593027A (OSRAM) |
| PA (1) | PA8850101A1 (OSRAM) |
| PE (1) | PE20120340A1 (OSRAM) |
| SG (1) | SG171820A1 (OSRAM) |
| SV (1) | SV2011003924A (OSRAM) |
| TN (1) | TN2011000232A1 (OSRAM) |
| TW (1) | TWI454260B (OSRAM) |
| UA (1) | UA107069C2 (OSRAM) |
| UY (1) | UY32263A (OSRAM) |
| WO (1) | WO2010061357A1 (OSRAM) |
| ZA (1) | ZA201103925B (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0816777B2 (ja) | 1988-10-13 | 1996-02-21 | 富士写真フイルム株式会社 | 画像形成方法 |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| CA2796464C (en) * | 2010-04-16 | 2021-08-03 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| BR112013006769B1 (pt) | 2010-09-27 | 2021-02-02 | Morphosys Ag | combinação sinérgica |
| CA2821992A1 (en) | 2010-10-01 | 2012-04-05 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| HRP20220250T1 (hr) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe |
| SI2791160T1 (sl) | 2011-12-16 | 2022-07-29 | Modernatx, Inc. | Sestave modificirane MRNA |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| AU2013243952A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| PL2900232T3 (pl) | 2012-09-25 | 2018-05-30 | Morphosys Ag | Kombinacje i ich zastosowania |
| SMT202200337T1 (it) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Rna modificato al livello del terminale |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| MA39070A1 (fr) | 2014-07-31 | 2017-11-30 | Sanofi Sa | Anticorps anti-cd38 spécifiques pour le traitement de cancers humains |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| EA035979B1 (ru) | 2014-09-09 | 2020-09-08 | Янссен Байотек, Инк. | Варианты комбинированной терапии анти-cd38 антителами |
| KR102597989B1 (ko) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | 급성 골수성 백혈병을 치료하기 위한 항-cd38 항체 |
| IL319936A (en) | 2015-05-20 | 2025-05-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| EP4516319A3 (en) | 2015-11-03 | 2025-05-07 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
| CN109689690B (zh) | 2016-07-15 | 2023-10-03 | 武田药品工业株式会社 | 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| US20210145778A1 (en) * | 2018-01-01 | 2021-05-20 | Orbicular Pharmaceutical Technologies Pvt. Ltd. | Stable Liquid Compositions of Melphalan |
| CA3088199A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| AU2019347666B2 (en) | 2018-09-28 | 2025-10-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| CN113574071B (zh) | 2019-03-15 | 2025-03-25 | 莫佛塞斯公司 | 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| IL293563A (en) | 2019-12-05 | 2022-08-01 | Sanofi Aventis Us Llc | Formulations of anti-cd38 antibodies for subcutaneous administration |
| TW202235435A (zh) | 2021-01-14 | 2022-09-16 | 德商莫菲西斯公司 | 抗cd38抗體及其用途 |
| TW202302642A (zh) | 2021-03-01 | 2023-01-16 | 德商莫菲西斯公司 | 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體 |
| TW202321303A (zh) | 2021-07-19 | 2023-06-01 | 德商莫菲西斯公司 | 抗pla2r自體抗體媒介膜性腎病變之治療 |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB750155A (en) | 1953-03-17 | 1956-06-13 | Nat Res Dev | Substituted alanines |
| US3032585A (en) | 1954-12-03 | 1962-05-01 | Nat Res Dev | Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| DE69800716T2 (de) | 1997-04-14 | 2001-09-20 | Micromet Gesellschaft Fuer Biomedizinische Forschung Mbh | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2329940A1 (en) * | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| GB0221574D0 (en) | 2002-09-17 | 2002-10-23 | Isis Innovation | Treatments |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| PL2081595T3 (pl) | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| US20080092384A1 (en) * | 2006-10-16 | 2008-04-24 | Schaake Mark D | Installation of Middle Bearing for a Crankshaft |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
-
2008
- 2008-11-28 EP EP08291116A patent/EP2191840A1/en not_active Ceased
-
2009
- 2009-11-25 AR ARP090104545A patent/AR074219A1/es not_active Application Discontinuation
- 2009-11-25 TW TW098140158A patent/TWI454260B/zh active
- 2009-11-25 UY UY0001032263A patent/UY32263A/es not_active Application Discontinuation
- 2009-11-25 PA PA20098850101A patent/PA8850101A1/es unknown
- 2009-11-27 CA CA2744990A patent/CA2744990C/en not_active Expired - Fee Related
- 2009-11-27 WO PCT/IB2009/055389 patent/WO2010061357A1/en not_active Ceased
- 2009-11-27 NZ NZ593027A patent/NZ593027A/xx unknown
- 2009-11-27 JP JP2011538092A patent/JP2012510461A/ja not_active Withdrawn
- 2009-11-27 MY MYPI2011002367A patent/MY164577A/en unknown
- 2009-11-27 KR KR1020117014746A patent/KR101733252B1/ko active Active
- 2009-11-27 EP EP09775302A patent/EP2370094A1/en not_active Withdrawn
- 2009-11-27 BR BRPI0921864-5A patent/BRPI0921864B1/pt active IP Right Grant
- 2009-11-27 AU AU2009321249A patent/AU2009321249B2/en active Active
- 2009-11-27 UA UAA201108006A patent/UA107069C2/uk unknown
- 2009-11-27 SG SG2011037967A patent/SG171820A1/en unknown
- 2009-11-27 US US13/130,862 patent/US9259406B2/en active Active
- 2009-11-27 PE PE2011001107A patent/PE20120340A1/es active IP Right Grant
- 2009-11-27 MX MX2011005670A patent/MX342625B/es active IP Right Grant
- 2009-11-27 ME MEP-2011-93A patent/ME01136B/me unknown
- 2009-11-27 EA EA201100864A patent/EA026867B1/ru not_active IP Right Cessation
- 2009-11-27 CN CN200980148094.4A patent/CN102264385B/zh active Active
-
2011
- 2011-05-11 TN TN2011000232A patent/TN2011000232A1/fr unknown
- 2011-05-19 EC EC2011011062A patent/ECSP11011062A/es unknown
- 2011-05-24 IL IL213116A patent/IL213116B/en active IP Right Grant
- 2011-05-26 CR CR20110280A patent/CR20110280A/es unknown
- 2011-05-27 ZA ZA2011/03925A patent/ZA201103925B/en unknown
- 2011-05-27 CL CL2011001254A patent/CL2011001254A1/es unknown
- 2011-05-27 HN HN2011001417A patent/HN2011001417A/es unknown
- 2011-05-27 SV SV2011003924A patent/SV2011003924A/es unknown
- 2011-05-27 CO CO11065644A patent/CO6440557A2/es unknown
- 2011-05-27 NI NI201100105A patent/NI201100105A/es unknown
- 2011-06-13 MA MA33937A patent/MA32896B1/fr unknown
-
2015
- 2015-05-27 JP JP2015107404A patent/JP6148696B2/ja active Active
-
2017
- 2017-03-01 JP JP2017037860A patent/JP2017141233A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012510461A5 (OSRAM) | ||
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| AR073425A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente la cd38 y la citarabina | |
| AR074219A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
| JP2020500538A5 (OSRAM) | ||
| AR086579A1 (es) | Proteinas de union a antigeno | |
| JP2016536314A5 (OSRAM) | ||
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| AR071891A1 (es) | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) | |
| JP2013544492A5 (OSRAM) | ||
| JP2012136541A5 (OSRAM) | ||
| PH12016500859A1 (en) | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use | |
| JP2013502204A5 (OSRAM) | ||
| RU2014143784A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря | |
| AR074220A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso | |
| JP2017528476A5 (OSRAM) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| IN2012DN01328A (OSRAM) | ||
| HRP20161740T1 (hr) | Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b | |
| JP2020508303A5 (OSRAM) | ||
| RU2014143785A (ru) | Фармацевтическая композиция для лечения и/или предотвращения рака печени | |
| JP2017528462A5 (OSRAM) | ||
| JP2014076062A5 (OSRAM) | ||
| JP2013520996A5 (OSRAM) | ||
| NZ599405A (en) | Targeted binding agents against b7-h1 |